Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial

Caroline Robert(Institut Gustave Roussy), Jean‐Jacques Grob(Aix-Marseille Université), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Ana Arance Fernández(Hospital Clínic de Barcelona), Matthew Squires(Novartis (United States)), Delphine Allard, Egbert de Jong(Tris Pharma (United States)), Shensi Shen(Sichuan University)

Cancer Research

July 1, 2018

Cited by 1

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|The Lancet|2012|3k

|New England Journal of Medicine|2014|2k

Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with <i>BRAF</i> V600E/K-mutant melanoma in the COMBAT trial